Azenta, Inc. announced the full repayment of a $35 million secured vendor loan extended to Thelema S.à r.l. in connection with the July 1, 2026 sale of its subsidiary B Medical Systems. The borrower repaid the principal plus accrued interest on September 3, 2026, totaling $35,373,333, prior to the loan's maturity. This repayment satisfies all obligations under the Vendor Loan Agreement and releases the share pledge securing the transaction. Consequently, Azenta has now received the entire $63 million purchase price for B Medical Systems in cash, completing the divestiture and eliminating credit exposure associated with the deal. Azenta operates as a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions globally.

On August 6, 2026, Azenta appointed Erik J. Bello as Vice President and Chief Accounting Officer, effective August 31, 2026. Lawrence Lin will cease serving as principal accounting officer but remains Executive Vice President and Chief Financial Officer. Mr. Bello receives a $380,000 annual base salary, an $80,000 sign-on bonus, and equity grants totaling $450,000 over two years. Azenta operates in the life sciences technology sector, providing instruments, reagents, and services for research and development.

Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations reaching $161 million, a 12% increase year over year. Organic growth was 9%, driven by Sample Management Solutions ($88 million) and Multiomics ($73 million). The company reported a diluted EPS of $(0.03) from continuing operations and total diluted EPS of $0.05. Adjusted EBITDA for continuing operations was $18 million, with an adjusted EBITDA margin of 11.4%. Azenta updated its full-year fiscal 2026 guidance, now expecting total reported revenue between $613 million and $618 million and Adjusted EBITDA between $59 million and $62 million. The company ended the quarter with $529 million in cash and liquidity. As of June 30, 2026, Azenta had repurchased 2.3 million shares for $50 million under its 2025 share repurchase program. Azenta is a provider of life sciences solutions, offering cold-chain sample management and multiomics services to pharmaceutical, biotech, and academic institutions.

Azenta, Inc. completed the sale of B Medical Systems S.à r.l. to Thelema S.à r.l. on July 1, 2026, for an aggregate purchase price of $63 million. The consideration consists of $28 million in cash and a $35 million secured term loan provided by Azenta Germany GmbH to Thelema. The vendor loan carries a 6.0% annual interest rate and matures three months after funding. The transaction is a related party deal, as Thelema is majority owned by Luc Provost, a Company Vice President and CEO of the acquired entity. The loan is secured by a first-priority pledge of 100% of B Medical's equity interests. Azenta provides life sciences tools and services.